Blood Test With AI to Find Early Lung Cancer Risk in COPD Patients
Tests a blood sample and AI risk scoring to identify COPD patients needing lung scans.
Plain-language title generated from the registry record
Registry title: Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection
Key facts
- Where
- Vejle, DenmarkSee the 2 sites
Where in Denmark
- General practices, Vejle areaVejle, DenmarkTaking people
- Lillebaelt Hospital Vejle, University Hospital of Southern DenmarkVejle, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vejle Hospital
- Trial code
- NCT07552584
- Record updated
- 3 June 2026
- Original description
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).Read full original descriptionShow less
Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).
Patients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest.
The primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting.
The secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.
Inclusion: Diagnosed with COPD; => 50 years; Former or current smoker; Speaks and understands Danish; Able to give informed consent to participation.
Exclusion: Received active treatment for cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri); Diagnosed with cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri); Presents with symptoms giving suspicion of cancer (except non-melanoma skin cancer and carcinoma in situ cervicis uteri); In a condition not allowing diagnostic workup for or treatment of lung cancer; Had a CT scan of the thorax within 6 months; Does not have Eboks (electronic communication with Danish authorities).